New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Changhua site meets international regulatory standards for global medical applications
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The company will provide the necessary response to USFDA within stipulated 15 days
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Subscribe To Our Newsletter & Stay Updated
